Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IWWM-11 2022 | Future considerations for the treatment of Waldenström’s macroglobulinemia

Patrizia Mondello • 28 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia BTK inhibitors

Patrizia Mondello, MD, PhD, Mayo Clinic, Rochester, MN, briefly discusses the importance of improving treatment options for patients with Waldenström’s macroglobulinemia (WM), and the potential role of combination approaches and immunotherapies. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Patrizia Mondello

Outcomes of R-CHOP versus BR in follicular lymphoma based on PET SUVs 3:10
Outcomes of R-CHOP versus BR in follicular lymphoma based on PET SUVs
Patrizia Mondello • 8 Dec 2024
A study investigating the impact of DLBCL in the tissue biopsy on outcomes for patients with FL3B 3:36
A study investigating the impact of DLBCL in the tissue biopsy on outcomes for patients with FL3B
Patrizia Mondello • 8 Dec 2024
Silencing GNAS to improve the efficacy of HDAC3 inhibitors in DLBCL and FL with wild-type CREBBP 2:53
Silencing GNAS to improve the efficacy of HDAC3 inhibitors in DLBCL and FL with wild-type CREBBP
Patrizia Mondello • 18 Oct 2024
A study using multi-omics to characterize molecular clusters in IgM MGUS and WM 3:50
A study using multi-omics to characterize molecular clusters in IgM MGUS and WM
Patrizia Mondello • 18 Oct 2024

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals